Top Qs
Timeline
Chat
Perspective
Masud Husain
British professor of neuroscience, editor of Brain From Wikipedia, the free encyclopedia
Remove ads
Masud Husain FRCP FMedSci[2] is a clinical neurologist and neuroscientist at the University of Oxford.[3][1] He is Professor of Neurology & Cognitive Neuroscience at the Nuffield Department of Clinical Neurosciences[4] and Departmental of Experimental Psychology,[5] University of Oxford, a Professorial Fellow at New College, Oxford,[6] and Editor-in-Chief of the journal Brain.[7][8] He was born in East Pakistan, now Bangladesh.[citation needed]
Remove ads
Education
Husain was educated at King Edward VI Camp Hill School for Boys, Birmingham, and studied medicine at the University of Oxford where he was a student at New College, Oxford and received a Bachelor of Medicine, Bachelor of Surgery (BMBCh) degree[5] followed by a DPhil in 1987.[9]
Research and career
Summarize
Perspective
Husain held a Harkness Fellowship as a postdoctoral fellow in the laboratory of Richard A. Andersen at Massachusetts Institute of Technology (MIT).[10] He completed his clinical and neurological training at hospitals in Oxford and London.[4]
Husain's research focuses on cognitive functions in people with neurological diseases and healthy people.[4][5][11][12][13][14][15][16][17]
In an editorial in 2025, Husain criticised the rise of Bullshit Jobs in Universities in the United Kingdom.[7]
Attention and inattention
His work on people with hemispatial neglect following stroke demonstrated several novel components of this syndrome. Using the attentional blink paradigm he showed that there were non-spatial, selective attention deficits in these patients,[18] in addition to their well-established directional attentional bias. Subsequent behavioural studies revealed that some people with hemispatial neglect can also suffer from impaired spatial working memory,[19] often revisiting locations without being aware that they have fixated them before.[20][21] Some may have poor sustained attention as measured on vigilance tasks,[22] or even directional motor deficits as indexed by paradigms where the spatial location of a visual target is dissociated from direction of movement required to reach it.[23][24] These findings provided further evidence for neglect being a multi-component syndrome, with different patients having different deficits, depending upon the extent of their lesion.[25][26] Critical brain regions associated with neglect that were identified by this work, included the right inferior posterior parietal and frontal regions.[27][28] Experimental medicine studies by Husain's group using the dopamine agonist rotigotine[29] and the noradrenergic agonist guanfacine[30][31] demonstrated that these drugs can ameliorate hemispatial neglect to some extent by improving attention.
Visual short-term or working memory
By using new methods to measure the precision of recall in healthy people, work in Husain's lab challenged the view that capacity of visual short-term memory or working memory is limited to a fixed number of items.[32][33] Instead, this research revealed that although short-term memory is a highly limited resource, it can be flexibly deployed depending upon task demands.[34] This work led to the application of new methods to measure short-term memory in patients with Alzheimer's disease,[35][36] Parkinson's disease[35][36][37] and individuals at risk of developing these conditions.[35][36][37][38] The techniques that have been developed can provide more sensitive ways to measure short-term memory than traditional methods.[39] They have also revealed how different mechanisms might underlie short-term memory disorders in different neurological conditions.[36]
Motivation, apathy and initiation of action
Work from Husain's lab showed that lesions to ventral basal ganglia leads to a condition of profound apathy, manifest as a lack of motivation to initiate action and specifically attributable to a deficit in reward sensitivity.[40] Using the dopamine receptor agonist ropinirole, it was possible to improve reward sensitivity, restore motivational vigour and reverse apathy.[40] These observations stimulated larger-scale studies in Parkinson's disease, a condition associated with basal ganglia pathology and often debilitating apathy. The syndrome of pathological apathy in Parkinson's disease[41][42] and small vessel cerebrovascular disease[43][44] was found to be characterised by reduced sensitivity to rewards, a deficit that could be ameliorated by dopaminergic drugs in Parkinson's disease.[41][42] This has led to a theoretical framework to understand mechanisms underlying apathy across brain disorders which incorporates concepts from cost-benefit decision making to formalise how people differ in their willingness to engage in effort in order to obtain potential rewards.[45]
The basal ganglia are considered to be essential for linking motivation to action systems.[46] Outputs of the basal ganglia are strongly connected to medial frontal cortex. Husain's group identified a mechanism that resolves competition between conflicting action plans, in medial frontal brain regions, including the supplementary eye field,[47] supplementary motor area and pre-supplementary motor area.[48][49] A key component of voluntary control paradoxically appears to involve inhibition of unwanted actions that are primed automatically by seeing objects around us.[50] This control is lost following supplementary motor area and pre-supplementary motor area lesions. Findings from lesion, stimulation and physiological studies were incorporated to provide a new theoretical framework for the role of the supplementary motor area and pre-supplementary motor area complex.[51]
Awards and honours
Husain held a Wellcome Trust Senior Research Fellowship at Imperial College London (2000-2007) and University College London (UCL) (2007–12). He was awarded a Wellcome Trust Principal Research Fellowship (2012-2023) and elected Fellow of the Academy of Medical Sciences (FMedSci) in 2008.[2] Husain was awarded the Graham Bull Prize in Clinical Science by the Royal College of Physicians in 2006, British Neuropsychological Society's Elizabeth Warrington Prize (2006),[52] and the European Academy of Neurology Investigator Award (2016).[53] He is Fellow of the American Academy of Neurology (2018) and Fellow of the European Academy of Neurology (2018),[54] and is co-lead of the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre Dementia theme (2022 -)[55] and Dementia Research Oxford at the University of Oxford.[56]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads